Genome-wide analysis of androgen receptor binding and gene regulation in two CWR22-derived prostate cancer cell lines

Endocrine-Related Cancer

Volumn 17, Issue 4, 2010, Pages 857-873

  Chen, Honglin ^a   Libertini, Stephen J ^a,c   George, Michael ^a   Dandekar, Satya ^a   Tepper, Clifford G ^a   Al Bataina, Bushra ^a   Kung, Hsing Jien ^a,b   Ghosh, Paramita M ^a,b   Mudryj, Maria ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VA NORTHERN CALIFORNIA HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; CCAAT ENHANCER BINDING PROTEIN DELTA;

ARTICLE; CANCER CELL CULTURE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DNA MICROARRAY; GENE CONTROL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENOME ANALYSIS; HORMONE RESPONSE; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; PROSTATE CANCER; RECEPTOR BINDING; TRANSCRIPTION REGULATION;

BINDING SITES; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; DIHYDROTESTOSTERONE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; NEOPLASMS, HORMONE-DEPENDENT; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RNA, MESSENGER;

EID: 78649820197     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1677/ERC-10-0081     Document Type: Article

References (54)

1. Beheshti B, Vukovic B, Marrano P, Squire JA & Park PC 2002 Resolution of genotypic heterogeneity in prostate tumors using polymerase chain reaction and comparative genomic hybridization on microdissected carcinoma and prostatic intraepithelial neoplasia foci. Cancer Genetics and Cytogenetics 137 15-22. (doi:10.1016/S0165-4608(02)00540-X)
2. Belandia B, Powell SM, Garcia-Pedrero JM, Walker MM, Bevan CL & Parker MG 2005 Hey1, a mediator of Notch signaling, is an androgen receptor corepressor. Molecular and Cellular Biology 25 1425-1436. (doi:10.1128/MCB.25.4. 1425-1436.2005) (Pubitemid 40204919)
3. Bernstein BE, Kamal M, Lindblad-Toh K, Bekiranov S, Bailey DK, Huebert DJ, McMahon S, Karlsson EK, Kulbokas EJ III, Gingeras TR et al. 2005 Genomic maps and comparative analysis of histone modifications in human and mouse. Cell 120 169-181. (doi:10.1016/j.cell.2005.01.001)
4. van Bokhoven A, Varella-Garcia M, Korch C, Johannes WU, Smith EE, Miller HL, Nordeen SK, Miller GJ & Lucia MS 2003 Molecular characterization of human prostate carcinoma cell lines. Prostate 57 205-225. (doi:10.1002/pros. 10290)
5. Borgono CA & Diamandis EP 2004 The emerging roles of human tissue kallikreins in cancer. Nature Reviews. Cancer 4 876-890. (doi:10.1038/nrc1474)
6. Butcher NJ, Tetlow NL, Cheung C, Broadhurst GM & Minchin RF 2007 Induction of human arylamine N-acetyltransferase type I by androgens in human prostate cancer cells. Cancer Research 67 85-92. (doi:10.1158/0008-5472.CAN-06- 2635) (Pubitemid 46142762)
7. Carroll JS, Meyer CA, Song J, Li W, Geistlinger TR, Eeckhoute J, Brodsky AS, Keeton EK, Fertuck KC, Hall GF et al. 2006 Genome-wide analysis of estrogen receptor binding sites. Nature Genetics 38 1289-1297. (doi:10.1038/ng1901)
8. Cawley S, Bekiranov S, Ng HH, Kapranov P, Sekinger EA, Kampa D, Piccolboni A, Sementchenko V, Cheng J, Williams AJ et al. 2004 Unbiased mapping of transcription factor binding sites along human chromosomes 21 and 22 points to widespread regulation of noncoding RNAs. Cell 116 499-509. (doi:10.1016/S0092-8674(04)00127-8)
9. Chen H, Libertini SJ, Wang Y, Kung HJ, Ghosh P & Mudryj M 2010 ERK regulates calpain 2-induced androgen receptor proteolysis in CWR22 relapsed prostate tumor cell lines. Journal of Biological Chemistry 285 2368-2374. (doi:10.1074/jbc.M109.049379)
10. Cirillo LA, Lin FR, Cuesta I, Friedman D, Jarnik M & Zaret KS 2002 Opening of compacted chromatin by early developmental transcription factors HNF3 (FoxA) and GATA-4. Molecular Cell 9 279-289. (doi:10.1016/S1097-2765(02)00459- 8)
11. Desai SJ, Ma AH, Tepper CG, Chen HW & Kung HJ 2006 Inappropriate activation of the androgen receptor by nonsteroids: involvement of the Src kinase pathway and its therapeutic implications. Cancer Research 66 10449-10459. (doi:10.1158/0008-5472.CAN-06-2582)
12. Devlin HL & Mudryj M 2009 Progression of prostate cancer: multiple pathways to androgen independence. Cancer Letters 274 177-186. (doi:10.1016/j.canlet.2008.06.007)
13. Fischer A & Gessler M 2007 Delta-Notch - and then? Protein interactions and proposed modes of repression by Hes and Hey bHLH factors Nucleic Acids Research 35 4583-4596. (doi:10.1093/nar/gkm477)
14. Gittes RF 1991 Carcinoma of the prostate. New England Journal of Medicine 324 236-245.
15. Gnanapragasam VJ, Robson CN, Neal DE & Leung HY 2002 Regulation of FGF8 expression by the androgen receptor in human prostate cancer. Oncogene 21 5069-5080. (doi:10.1038/sj.onc.1205663)
16. Gregory CW, Hamil KG, Kim D, Hall SH, Pretlow TG, Mohler JL & French FS 1998 Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes. Cancer Research 58 5718-5724.
17. Gregory CW, He B & Wilson EM 2001 The putative androgen receptor-A form results from in vitro proteolysis. Journal of Molecular Endocrinology 27 309-319. (doi:10.1677/jme.0.0270309)
18. He WW, Sciavolino PJ, Wing J, Augustus M, Hudson P, Meissner PS, Curtis RT, Shell BK, Bostwick DG, Tindall DJ et al. 1997 A novel human prostate-specific, androgen-regulated homeobox gene (NKX3.1) that maps to 8p21, a region frequently deleted in prostate cancer. Genomics 43 69-77. (doi:10.1006/geno.1997.4715)
19. Heemers HV, Regan KM, Schmidt LJ, Anderson SK, Ballman KV & Tindall DJ 2009 Androgen modulation of coregulator expression in prostate cancer cells. Molecular Endocrinology 23 572-583. (doi:10.1210/me.2008-0363)
20. Hosack DA, Dennis G Jr, Sherman BT, Lane HC & Lempicki RA 2003 Identifying biological themes within lists of genes with EASE. Genome Biology 4 P4. (doi:10.1186/gb-2003-4-6-p4)
21. Huggins C & Hodges CV 1941 The effects of castration, of estrogen and of androgen injection on the serum phosphatases in metastatic carcinoma of the prostate. Cancer Research 1 293-297.
22. Ji H & Wong WH 2005 TileMap: create chromosomal map of tiling array hybridizations. Bioinformatics 21 3629-3636. (doi:10.1093/bioinformatics/bti593)
23. Ji H, Jiang H, Ma W, Johnson DS, Myers RM & Wong WH 2008 An integrated software system for analyzing ChIP-chip and ChIP-seq data. Nature Biotechnology 26 1293-1300. (doi:10.1038/nbt.1505)
24. Jia L, Berman BP, Jariwala U, Yan X, Cogan JP, Walters A, Chen T, Buchanan G, Frenkel B & Coetzee GA 2008 Genomic androgen receptor-occupied regions with different functions, defined by histone acetylation, coregulators and transcriptional capacity. PLoS ONE 3 e3645. (doi:10.1371/journal.pone. 0003645)
25. Jia L, Landan G, Pomerantz M, Jaschek R, Herman P, Reich D, Yan C, Khalid O, Kantoff P, Oh W et al. 2009 Functional enhancers at the gene-poor 8q24 cancer-linked locus. PLoS Genetics 5 e1000597. (doi:10.1371/journal.pgen. 1000597)
26. Jiang F & Wang Z 2004 Identification and characterization of PLZF as a prostatic androgen-responsive gene. Prostate 59 426-435. (doi:10.1002/pros. 20000)
27. Ko CY, Hsu HC, Shen MR, Chang WC & Wang JM 2008 Epigenetic silencing of CCAAT/enhancer-binding protein delta activity by YY1/polycomb group/DNA methyltransferase complex. Journal of Biological Chemistry 283 30919-30932. (doi:10.1074/jbc.M804029200)
28. Landers KA, Samaratunga H, Teng L, Buck M, Burger MJ, Scells B, Lavin MF & Gardiner RA 2008 Identification of claudin-4 as a marker highly overexpressed in both primary and metastatic prostate cancer. British Journal of Cancer 99 491-501. (doi:10.1038/sj.bjc.6604486)
29. Li P, Yu X, Ge K, Melamed J, Roeder RG & Wang Z 2002 Heterogeneous expression and functions of androgen receptor co-factors in primary prostate cancer. American Journal of Pathology 161 1467-1474.
30. Lin B, Ferguson C, White JT, Wang S, Vessella R, True LD, Hood L & Nelson PS 1999 Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2. Cancer Research 59 4180-4184.
31. Lin B, Wang J, Hong X, Yan X, Hwang D, Cho JH, Yi D, Utleg AG, Fang X, Schones DE et al. 2009 Integrated expression profiling and ChIP-seq analyses of the growth inhibition response program of the androgen receptor. PLoS ONE 4 e6589. (doi:10.1371/journal.pone.0006589)
32. Liu AY, Roudier MP & True LD 2004 Heterogeneity in primary and metastatic prostate cancer as defined by cell surface CD profile. American Journal of Pathology 165 1543-1556.
33. Louie MC, Yang HQ, Ma AH, Xu W, Zou JX, Kung HJ & Chen HW 2003 Androgen-induced recruitment of RNA polymerase II to a nuclear receptor-p160 coactivator complex. PNAS 100 2226-2230. (doi:10.1073/pnas.0437824100) (Pubitemid 36297481)
34. Lu S, Jenster G & Epner DE 2000 Androgen induction of cyclin-dependent kinase inhibitor p21 gene: role of androgen receptor and transcription factor Sp1 complex. Molecular Endocrinology 14 753-760. (doi:10.1210/me.14.5.753)
35. Lupien M, Eeckhoute J, Meyer CA, Wang Q, Zhang Y, Li W, Carroll JS, Liu XS & Brown M 2008 FoxA1 translates epigenetic signatures into enhancer-driven lineagespecific transcription. Cell 132 958-970. (doi:10.1016/j.cell.2008.01.018)
36. Nagabhushan M, Miller CM, Pretlow TP, Giaconia JM, Edgehouse NL, Schwartz S, Kung HJ, de Vere White RW, Gumerlock PH, Resnick MI et al. 1996 CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar. Cancer Research 56 3042-3046.
37. Nelson PS, Clegg N, Arnold H, Ferguson C, Bonham M, White J, Hood L & Lin B 2002 The program of androgen-responsive genes in neoplastic prostate epithelium. PNAS 99 11890-11895. (doi:10.1073/pnas.182376299)
38. Nwosu V, Carpten J, Trent JM & Sheridan R 2001 Heterogeneity of genetic alterations in prostate cancer: evidence of the complex nature of the disease. Human Molecular Genetics 10 2313-2318. (doi:10.1093/hmg/10.20.2313)
39. Riegman PH, Vlietstra RJ, van der Korput JA, Brinkmann AO & Trapman J 1991 The promoter of the prostate-specific antigen gene contains a functional androgen responsive element. Molecular Endocrinology 5 1921-1930. (doi:10.1210/mend-5-12-1921)
40. Ruizeveld de Winter JA, Janssen PJ, Sleddens HM, Verleun-Mooijman MC, Trapman J, Brinkmann AO, Santerse AB, Schroder FH & van der Kwast TH 1994 Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. American Journal of Pathology 144 735-746.
41. Shah RB, Mehra R, Chinnaiyan AM, Shen R, Ghosh D, Zhou M, Macvicar GR, Varambally S, Harwood J, Bismar TA et al. 2004 Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Research 64 9209-9216. (doi:10.1158/0008-5472.CAN-04-2442)
42. Takayama K, Kaneshiro K, Tsutsumi S, Horie-Inoue K, Ikeda K, Urano T, Ijichi N, Ouchi Y, Shirahige K, Aburatani H et al. 2007 Identification of novel androgen response genes in prostate cancer cells by coupling chromatin immunoprecipitation and genomic microarray analysis. Oncogene 26 4453-4463. (doi:10.1038/sj.onc.1210229) (Pubitemid 47014467)
43. Takayama K, Tsutsumi S, Suzuki T, Horie-Inoue K, Ikeda K, Kaneshiro K, Fujimura T, Kumagai J, Urano T, Sakaki Y et al. 2009 Amyloid precursor protein is a primary androgen target gene that promotes prostate cancer growth. Cancer Research 69 137-142. (doi:10.1158/0008-5472.CAN-08-3633)
44. Tan J, Sharief Y, Hamil KG, Gregory CW, Zang DY, Sar M, Gumerlock PH, deVere White RW, Pretlow TG, Harris SE et al. 1997 Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells. Molecular Endocrinology 11 450-459. (doi:10.1210/me.11.4.450)
45. Tepper CG, Boucher DL, Ryan PE, Ma AH, Xia L, Lee LF, Pretlow TG & Kung HJ 2002 Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line. Cancer Research 62 6606-6614.
46. Thomas MA, Preece DM & Bentel JM 2010 Androgen regulation of the prostatic tumour suppressor NKX3.1 is mediated by its 30 untranslated region. Biochemical Journal 425 575-583. (doi:10.1042/BJ20091109)
47. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R et al. 2005 Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310 644-648. (doi:10.1126/science.1117679)
48. Viger RS, Guittot SM, Anttonen M, Wilson DB & Heikinheimo M 2008 Role of the GATA family of transcription factors in endocrine development, function, and disease. Molecular Endocrinology 22 781-798. (doi:10.1210/me.2007-0513)
49. Wainstein MA, He F, Robinson D, Kung HJ, Schwartz S, Giaconia JM, Edgehouse NL, Pretlow TP, Bodner DR, Kursh ED et al. 1994 CWR22: androgen-dependent xenograft model derived from a primary human prostatic carcinoma. Cancer Research 54 6049-6052.
50. Wang Q, Li W, Liu XS, Carroll JS, Janne OA, Keeton EK, Chinnaiyan AM, Pienta KJ & Brown M 2007 A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Molecular Cell 27 380-392. (doi:10.1016/j.molcel.2007.05.041)
51. Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J, Chen Z, Beroukhim R, Wang H, Lupien M et al. 2009 Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 138 245-256. (doi:10.1016/j.cell.2009.04.056)
52. Whitbread AK, Veveris-Lowe TL, Lawrence MG, Nicol DL & Clements JA 2006 The role of kallikrein-related peptidases in prostate cancer: potential involvement in an epithelial to mesenchymal transition. Biological Chemistry 387 707-714. (doi:10.1515/BC.2006.089)
53. Xu LL, Shi Y, Petrovics G, Sun C, Makarem M, Zhang W, Sesterhenn IA, McLeod DG, Sun L, Moul JW et al. 2003 PMEPA1, an androgen-regulated NEDD4-binding protein, exhibits cell growth inhibitory function and decreased expression during prostate cancer progression. Cancer Research 63 4299-4304.
54. Yang G, Gregory CW, Shang Q, O'Brien DA & Zhang YL 2001 Differential expression of CCAAT/enhancer-binding protein-delta (c/EBPdelta) in rat androgen-dependent tissues and human prostate cancer. Journal of Andrology 22 471-480.